Zobrazeno 1 - 10
of 58
pro vyhledávání: '"M. Chazard"'
Publikováno v:
Lung Cancer. 31:295-301
A dose escalation study of paclitaxel in combination with vinorelbine was conducted in 21 patients with previously untreated stage IIIb or IV non-small cell lung cancer (NSCLC). All three patients treated with the initial dose of paclitaxel 135 mg/m2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aeba6e027487fc4592f1d4329e26d1a
https://doi.org/10.1016/s0169-5002(00)00193-8
https://doi.org/10.1016/s0169-5002(00)00193-8
Autor:
Catherine Lhommé, Moïse Namer, Jean-Paul Guastalla, F. Chauvin, P. Goupil, J.F. Héron, P. Charrot, P. Kerbrat, M. Chazard, I. Richard, F. Mayer
Publikováno v:
Annals of Oncology. 5:127-132
Summary Background Because of its antitumour activity and its pharmacological advantage when administered by the intraperitoneal route, carboplatin was studied in a phase II multicen-tric trial. The aim of the study was to determine the response rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2034da27771012517d27fbc14ad9a813
https://doi.org/10.1093/oxfordjournals.annonc.a058763
https://doi.org/10.1093/oxfordjournals.annonc.a058763
Autor:
Pierre Ruffié, R. Subirana, Thomas Tursz, T. Le Chevalier, M. Chazard, Pierre Baldeyrou, Rodrigo Arriagada, F. Thomas
Publikováno v:
Cancer. 67:2980-2983
This Phase II study evaluated the combination of two active agents in small cell lung carcinoma (SCLC): carboplatin and ifosfamide. Thirty previously untreated patients (27 men and 3 women) with a median age of 59 years were included in this study. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ba872d58b73be49a10398e8bd713fed
https://doi.org/10.1002/1097-0142(19910615)67:12<2980::aid-cncr2820671207>3.0.co
https://doi.org/10.1002/1097-0142(19910615)67:12<2980::aid-cncr2820671207>3.0.co
Publikováno v:
Bulletin du cancer. 83(4)
Despite their high efficiency in treating cancer of the uterine cervix, surgery and radiotherapy can not cure (local and/or metastatic disease) a certain number of patients with initially adverse risk factors, mostly local or regionally advanced cerv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4322b77b6b723b7371ea9a604697dafa
https://pubmed.ncbi.nlm.nih.gov/8680079
https://pubmed.ncbi.nlm.nih.gov/8680079
Autor:
G, Catimel, M, Spielmann, V, Dieras, L, Kayitalire, P, Pouillart, J P, Guastalla, P, Soler-Michel, N, Graffand, F, Garet, A, Dumortier, B, Pellae-Cosset, M, Chazard
Publikováno v:
Seminars in oncology. 23(1 Suppl 1)
Attempting to develop a new active, convenient regimen, we initiated a phase I study of paclitaxel (Taxol; Bristol-Myers squibb Company, Princeton, NJ) combined with epirubicin (Farmitalia Carlo Erba, Milan, Italy) in patients with metastatic breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::34baa1176b13fc95f96b7484f1e57c2e
https://pubmed.ncbi.nlm.nih.gov/8629032
https://pubmed.ncbi.nlm.nih.gov/8629032
Autor:
V, Dieras, M, Marty, N, Tubiana, L, Corette, F, Morvan, D, Serin, L, Mignot, M, Chazard, F, Garet, N, Onetto
Publikováno v:
Seminars in oncology. 22(4 Suppl 8)
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7353b68af7c488c7ea39b04fc0c8cfac
https://pubmed.ncbi.nlm.nih.gov/7638640
https://pubmed.ncbi.nlm.nih.gov/7638640
Publikováno v:
Bulletin du cancer. 81(3)
Taxol is the first of the taxanes, a new class of cytotoxic agents whose cellular target is the microtubules network. Taxol induces the polymerisation of the alpha and beta sub-units of the tubulin. This mechanism of action which is different from th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ac01005f1c489bf3f611769941462d9d
https://pubmed.ncbi.nlm.nih.gov/7894125
https://pubmed.ncbi.nlm.nih.gov/7894125
Autor:
J P, Guastalla, C, Lhomme, P, Kerbrat, F, Mayer, M, Namer, P, Goupil, P, Charrot, J F, Heron, M, Chazard, I, Richard
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 5(2)
Because of its antitumour activity and its pharmacological advantage when administered by the intraperitoneal route, carboplatin was studied in a phase II multicentric trial. The aim of the study was to determine the response rate and the toxicity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::231748c710e10b89f786cd4eea1ab91d
https://pubmed.ncbi.nlm.nih.gov/8186155
https://pubmed.ncbi.nlm.nih.gov/8186155
Autor:
T, Le Chevalier, F, Thomas, R, Subirana, P, Baldeyrou, P, Ruffie, R, Arriagada, M, Chazard, T, Tursz
Publikováno v:
Cancer. 67(12)
This Phase II study evaluated the combination of two active agents in small cell lung carcinoma (SCLC): carboplatin and ifosfamide. Thirty previously untreated patients (27 men and 3 women) with a median age of 59 years were included in this study. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0155db0e972d6c98ffc47cb518c092c7
https://pubmed.ncbi.nlm.nih.gov/1646067
https://pubmed.ncbi.nlm.nih.gov/1646067
Autor:
P, Kerbrat, J F, Héron, J P, Guastalla, C, Lhomme, A, Goupil, C, Toussaint, A, Rey, M, Chazard, L, Lenaz, M, George
Publikováno v:
Bulletin du cancer. 78(12)
Thirty female patients with ovarian cancer of poor prognosis were included in a chemotherapy trial using high dose IV carboplatin--800 mg/m2 every 5 weeks. The subjects had three to six cycles prior to second laparotomy. Twenty-eight patients were as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6b521fca377f91f97b20acf693748191
https://pubmed.ncbi.nlm.nih.gov/1786426
https://pubmed.ncbi.nlm.nih.gov/1786426